Pyxis Oncology’s (PYXS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report sent to investors on Monday,Benzinga reports. They currently have a $5.00 price target on the stock.

Separately, Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 price target on shares of Pyxis Oncology in a report on Wednesday, March 19th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.00.

Pyxis Oncology Price Performance

PYXS opened at $1.23 on Monday. The stock’s 50 day simple moving average is $1.05 and its 200 day simple moving average is $1.60. The firm has a market cap of $76.20 million, a price-to-earnings ratio of -1.19 and a beta of 1.15. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.39.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.06). As a group, sell-side analysts anticipate that Pyxis Oncology will post -1.04 EPS for the current year.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in PYXS. Barclays PLC lifted its stake in Pyxis Oncology by 275.0% in the third quarter. Barclays PLC now owns 64,089 shares of the company’s stock worth $235,000 after acquiring an additional 46,997 shares during the period. American Century Companies Inc. raised its holdings in Pyxis Oncology by 88.1% in the 4th quarter. American Century Companies Inc. now owns 299,937 shares of the company’s stock worth $468,000 after purchasing an additional 140,498 shares in the last quarter. Caption Management LLC purchased a new stake in shares of Pyxis Oncology in the 4th quarter worth about $35,000. Renaissance Technologies LLC lifted its position in shares of Pyxis Oncology by 83.0% in the 4th quarter. Renaissance Technologies LLC now owns 293,354 shares of the company’s stock worth $458,000 after purchasing an additional 133,018 shares during the period. Finally, Ridgeback Capital Investments L.P. bought a new stake in shares of Pyxis Oncology during the 4th quarter valued at about $560,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.